Merck has successfully completed a year of strategically important moves and achieved its objectives.   “We strengthened all three of Merck’s business sectors: Healthcare, Life Science and Performance Materials. With the acquisition of AZ, the offer to acquire Sigma-Aldrich and the alliance with Pfizer in immuno-oncology, we have laid the foundations for future growth,” said Karl-Ludwig Kley, chairman of the Executive Board of Merck. “These developments are the result of our long-term transfor...